Furthermore, CPZ reduced the SIRT1 protein level in both p53 wild-type (HCT116 and LoVo) and mutant (HCT15) cells (Supplementary Figure S2B), suggesting that CPZ is a SIRT1 inhibitor and can treat p53 mutant CRC cells by attenuating other SIRT1-dependent oncogenic signaling pathways; however, additional evidence supporting these inferences is required. Here, CPZ is linked to colorectal carcinoma.